Oncocyte's Presence at the MedTech Conference
Oncocyte Corp., a leader in the diagnostics technology arena, recently announced the attendance of its Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James at a prominent conference focused on MedTech, Digital Health, Life Science, and Diagnostic Tools. This event presents a vital opportunity for Oncocyte to connect with investors who are interested in the advancements of the company's innovative diagnostic solutions.
Engaging Investors One-on-One
During this leading conference, Oncocyte plans to hold one-on-one meetings with potential investors. Stakeholders are encouraged to reach out and schedule these discussions to explore how Oncocyte’s cutting-edge technology aligns with the future of diagnostics.
About the Conference
The MedTech, Digital Health, Life Science, and Diagnostic Tools Conference serves as a crucial platform for industry leaders to share insights and showcase their latest innovations. Events such as this foster collaboration among health tech companies, investors, and thought leaders driving change in the diagnostic landscape.
Innovative Products Transforming Healthcare
Oncocyte’s commitment to advancing diagnostic capabilities is exemplified through its product offerings. The company’s tests aim to enhance clarity and confidence for healthcare professionals and patients alike. Notable products include:
- VitaGraft™: A clinical blood-based test designed for solid organ transplantation monitoring.
- GraftAssure™: An RUO blood-based test for tracking organ transplant efficacy.
- DetermaIO™: A gene expression test assessing tumor microenvironments to predict responses to immunotherapies.
- DetermaCNI™: A blood-based tool for monitoring therapeutic effectiveness in cancer treatment.
The Impact of Oncocyte's Solutions
The innovative tests provided by Oncocyte play a pivotal role in improving patient outcomes. By focusing on personalized diagnostics, the company equips physicians with valuable data needed for tailored treatment plans. This level of precision is increasingly vital in today's healthcare environment.
Contact Information for Inquiries
For further information about Oncocyte's participation in the conference or details regarding their product range, interested parties can reach out to:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
Frequently Asked Questions
What is Oncocyte Corp. known for?
Oncocyte Corp. specializes in diagnostics technology, focusing on personalized testing solutions for solid organ transplantation and cancer patients.
What products does Oncocyte offer?
Oncocyte offers products like VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™, which enhance monitoring and diagnostic capabilities.
How can investors meet with Oncocyte's leadership?
Investors can schedule one-on-one meetings with Oncocyte's executives during the MedTech conference by contacting BTIG directly.
What is the significance of the MedTech conference?
The conference is vital for industry stakeholders to connect, share insights, and discuss advancements in medical technology and diagnostic tools.
How does Oncocyte improve patient outcomes?
Through its innovative diagnostic solutions, Oncocyte provides healthcare professionals with crucial data that aids in personalized treatment planning, ultimately improving patient care.
